The failure of dozens of clinical trials to improve outcomes from moderate-severe traumatic brain injury (TBI) has led to a broad consensus that new approaches are needed.
1 Current efforts recognize that TBI is not a single disease entity and therefore aim to develop more refined TBI classifications.
2,3 The goal is to implement a precision or personalized medicine approach by identifying variations of pathological anatomy and physiology to target treatments to patients whose conditions are likely to be responsive.
4 Such precision targeting of treatments to diagnosed pathological mechanisms was notably lacking in prior failed trials, which relied heavily on neuroprotection studies in animal models and largely neglected clinical investigation of disease processes. Thus, the last decade has seen increasing use of multimodal intracranial monitoring for patients in traumatic coma to characterize secondary injury mechanisms and provide neuroprotection through personalized optimization of brain physiology.
5,6